Insider buying last 90 days
No open-market insider purchases were filed for RCUS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RCUS insider filing, plotted on the chart in Gekko.Open RCUS in Gekko
NYSE: RCUS
Arcus Biosciences (RCUS) Stock Analysis & Forecast
Oct 12 close
$24.34−0.07 (−0.3%)
Gekko Brief
AI summaryOct 12 closeArcus Biosciences shares moved on a mix of sector pressure and company updates this week. Shares fell 6.1% to $23.04 on 8 October amid broad biotechnology sector selling unrelated to company news, while earlier in the week RCUS gained 1.49% to $24.80 ahead of an upcoming investor event on casdatifan data. The company's second-quarter 2026 revenue of $41.0 million surpassed consensus estimates of $22 million, despite a year-over-year decline and a net loss of $91.0 million, prompting Wall Street Zen to upgrade the stock from Sell to Hold.
RCUS closed at $24.34, down 0.3%, sitting between its 50-day average of $27.39 and 200-day average of $24.83. The GekkoIndex reads 64.8, placing the stock in the Accumulation zone. The current price stands 24.7% below the Gekko Fair Value of $32.33.
Arcus reports earnings after the close on 27 October, 15 days away and within a typical 20-trading-day holding period; its last report beat estimates with an EPS of -$0.72 against a -$0.98 estimate, with a -1.6% reaction. No insider, Congress or unusual options activity appears in the current window. Seasonality over the next 20 trading days has averaged 3.3% across 5 years, rising in 2 of them. An investor event on 20 October featuring new casdatifan data is also on the calendar within this stretch.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Arcus Biosciences price vs fair value
Close $24.34200-day averageGekko Fair Value $32.33
Arcus Biosciences quick facts
- Market cap
- $3.06B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.91
- Revenue, TTM
- $117.0M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.94
- Volume
- 1.34M avg 1.54M
- 1-year return
- +60.6%
- Typical daily move
- ±5%
- Typical 20-day move
- ±10.9%
- 50-day average
- $27.39
- 200-day average
- $24.83
- Next earnings
- Oct 27 after close
- Shares outstanding
- 125.8M
Arcus Biosciences swing-trade checklist
Arcus Biosciences scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $24.34 sits between the 50-day ($27.39) and 200-day ($24.83) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.8, Accumulation
Reading 64.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
24.7% below
Price is 24.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 15 days
Reports on Oct 27, 2026, 15 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+3.3% on average
From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Arcus Biosciences stock chart and price history
Arcus Biosciences closed at $24.34 on Oct 12, 2026, +60.6% over the past year, inside a 52-week range of $14.26 to $31.74.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.0%
- 3 months
- −14.1%
- 6 months
- +8.7%
- 1 year
- +60.6%
The full RCUS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RCUS in Gekko
Follow Arcus Biosciences through every session
Put RCUS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RCUS in GekkoFree for 7 days. No credit card required.
About Arcus Biosciences
Arcus Biosciences works on cancer treatments that are still moving through clinical testing rather than already sold to patients. Its pipeline spans several experimental compounds, including casdatifan for kidney cancer, domvanalimab and zimberelimab as antibody-based approaches, and quemliclustat, which targets an enzyme involved in tumor growth. Additional candidates such as AB598 and AB801 are being tested for gastrointestinal and lung cancers, placing the company's work across multiple stages of trial progress, from early-phase studies to later-phase trials.
The company advances some of this research through partnerships rather than working entirely on its own. It collaborates with AstraZeneca on trials combining its drug candidates with AstraZeneca compounds in lung cancer and kidney cancer patient groups, and it works with BVF Partners L.P. on discovering and developing treatments aimed at inflammatory conditions. As a clinical-stage operation, its activity centers on research and trial execution in the United States rather than on marketing approved products.
Arcus Biosciences was incorporated in 2015 and operates out of Hayward, California. Its shares are listed on the NYSE under the ticker RCUS.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- arcusbio.com
Arcus Biosciences GekkoIndex: the smart money zone
Arcus Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.8, in the Accumulation zone, up 0.3 points over five sessions.
64.8Accumulation
Up 0.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | −0.8% | +2.4% | ||
| Accumulation (current zone) | 230 | +1.3% | +1.7% | ||
| Neutral | 389 | +0.3% | +3.1% | ||
| Distribution | 26 | +1.1% | +0.8% | ||
| Selling | 2 | Too few readings yet | |||
Average RCUS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the RCUS price, zone by zone.Track RCUS in Gekko
Is Arcus Biosciences stock overvalued? Gekko Fair Value
Arcus Biosciences trades 24.7% below Gekko Fair Value of $32.33, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Arcus Biosciences shares are worth, recalculated every trading day.
$32.33
Gekko Fair Value, Oct 10, 2026
24.7% Undervalued
At the end of Aug 2026 the price was 16.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open RCUS in Gekko
Arcus Biosciences insider and Congress trading
No open-market insider purchases were filed for Arcus Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RCUS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RCUS, plotted on the chart in Gekko.Open RCUS in Gekko
Buybacks
Arcus Biosciences has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2021
- $6K
- As a share of market cap
- 0.00%
From company filings.
Arcus Biosciences earnings: next date and track record
Arcus Biosciences reports on Oct 27, 2026, after the close (15 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 27, 2026
Expected after the close, 15 days away
- EPS estimate
- −$0.88
- Revenue estimate
- $11.14M
6 of 8reports beat the EPS estimate
±4.4%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Arcus is advancing casdatifan (HIF-2-alpha inhibitor) as its top priority, targeting a $5-10B market opportunity in clear cell RCC. Phase III PEAK-1 trial (cas + cabozantinib) remains on track for enrollment completion by year-end. Following Merck's LITESPARK-012 failure, cas faces no frontline competition. Multiple new clinical collaborations announced with BMS, Summit Therapeutics, and AVEO. PEAK-20 frontline Phase III registrational trial expected to start by end of 2026.
- Guidance
- PEAK-1 Phase III enrollment expected complete by end of 2026. PEAK-20 frontline registrational trial on track to initiate by end of 2026. New casdatifan data expected over the next 6 months to demonstrate full market potential.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.72 est −$0.98 | $41.00M est $21.98M | −1.6% |
| May 5, 2026 | −$1.02 est −$0.83 | $17.00M est $29.48M | −0.2% |
| Feb 25, 2026 | −$0.89 est −$1.11 | $33.00M est $35.71M | −3.2% |
| Oct 28, 2025 | −$1.27 est −$1.33 | $26.00M est $24.94M | +9.1% |
| Aug 6, 2025 | −$0.08 est −$1.14 | $160.0M est $32.48M | −2.8% |
| May 6, 2025 | −$1.14 est −$1.02 | $28.00M est $37.36M | −10.4% |
| Feb 25, 2025 | −$1.03 est −$1.17 | $26.00M est $29.38M | −0.2% |
| Nov 6, 2024 | −$1.00 est −$1.07 | $48.00M est $32.06M | +7.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Arcus Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Arcus Biosciences is $39.91, +64.0% from the last close, from 11 firms rating the stock in the last 90 days.
$39.91consensus 12-month target, +64.0% from the last close
Now $24.34Avg $39.91
Low $23High $47
Each firm’s latest rating in the last 90 days: 11 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Bank of America Securities | $29 | +19.1% |
| Oct 3 | LifeSci Capital | $46 | +89.0% |
| Sep 30 | Wedbush | $43 | +76.7% |
| Sep 27 | LifeSci Capital | $46 | +89.0% |
| Sep 25 | H.C. Wainwright | $45 | +84.9% |
+1.7%average 20-day move after past Accumulation readings
+3.3%average move over the next 20 trading days in the last 5 years
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Arcus Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Arcus Biosciences averaged +3.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.4% | 4 of 5 |
| Next 10 trading days | +5.2% | 3 of 5 |
| Next 15 trading days | +4.8% | 2 of 5 |
| Next 20 trading days | +3.3% | 2 of 5 |
| Next 30 trading days | +13.7% | 3 of 5 |
For scale, RCUS’s typical 20-trading-day move in either direction is about 10.9%.
Arcus Biosciences market cap and key statistics
Arcus Biosciences’s market cap is $3.06B and revenue of $117.0M over the last twelve months.
Valuation
- Market cap
- $3.06B
- EPS, TTM
- −$3.91
- Gekko Fair Value
- $32.33
Trading
- Volume
- 1.34M
- Avg volume, 20 days
- 1.54M
- 52-week high
- $31.74
- 52-week low
- $14.26
- Shares outstanding
- 125.8M
Financials
- Revenue, TTM
- $117.0M
- Profit margin
- 0%
- Return on equity
- -90.8%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.94
- Typical daily move
- ±5%
- Typical 20-day move
- ±10.9%
Arcus Biosciences stock news this week
Coverage of Arcus Biosciences this week reads positive: 2 positive, 0 neutral and 1 negative headlines.
- Arcus Biosciences Announces New Employment Inducement GrantsBusiness Wire, Oct 9
- Arcus Biosciences Drops 6.1% Amid Sector-Wide SellingAlphaStreet, Oct 8
- Arcus Biosciences stock gains 1.49 percent ahead of data eventAD HOC NEWS, Oct 5
- Wall Street Zen upgrades Arcus Biosciences stock to HoldAD HOC NEWS, Oct 5
Arcus Biosciences peers
Arcus Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Arcus Biosciences stock FAQ
What is Arcus Biosciences’s market cap?
Arcus Biosciences’s market cap is $3.06B at the Oct 12, 2026 close of $24.34, with 125.8M shares outstanding.
What is the Arcus Biosciences stock forecast?
The consensus analyst 12-month price target for Arcus Biosciences is $39.91, +64.0% from the last close. Of the 11 firms that rated the stock in the last 90 days, 8 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Arcus Biosciences stock overvalued or undervalued?
On Gekko’s estimate Arcus Biosciences is undervalued: the Oct 12, 2026 close of $24.34 is 24.7% below Gekko Fair Value of $32.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Arcus Biosciences report earnings next?
Arcus Biosciences is expected to report on Oct 27, 2026, after the market closes (15 days away). Analysts expect earnings of −$0.88 per share on revenue of $11.14M. Arcus Biosciences beat the earnings estimate in 6 of its last 8 reports, moving 4.4% on average across the report.
What is Arcus Biosciences’s 52-week high and low?
Arcus Biosciences’s 52-week high is $31.74 and its 52-week low is $14.26; it closed at $24.34 on Oct 12, 2026, +60.6% over the past year. Over the last five years the shares peaked at $49.10 on Nov 22, 2021.
Is Arcus Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 2 as mixed (trend and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Arcus Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.